Innoventric
Innoventric develops transcatheter solutions for patients with structural heart disease.
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | $28.5m | Series B | |
| Total Funding | 000k | ||
Related Content
More about Innoventric
EditDeveloper of percutaneous devices designed to provide treatment of tricuspid regurgitation. The company's device offers functional tricuspid valve replacement that utilizes cross-caval anchoring and a unique multi-valve design, for long-lasting blood flow regulation, enabling patients with structural heart disease to improve their lifespan and quality of their life.
Keywords: Pharmaceuticals and Biotechnology, Blood Flow Regulation, Heart Device, Medical Device, Percutaneous Treatment, Percutaneous Valves, Structural Heart Intervention, Treatment Services, Tricuspid Treatment.
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.